Download PDF
Endoscopy 2000; 32(1): 42-48
DOI: 10.1055/s-2000-132
Original Article
Georg Thieme Verlag Stuttgart ·New York

Does Hyperbaric Oxygen Enhance the Effect of Photodynamic Therapy in Patients with Advanced Esophageal Carcinoma? A Clinical Pilot Study

A. Maier 1 , U. Anegg 1 , F. Tomaselli 1 , P. Rehak 2 , O. Sankin 1 , B. Fell 1 , H. Renner 1 , H. Pinter 1 , F. M. Smolle-Jüttner 1 , G. B. Friehs 1
  • 1 Department of Thoracic and Hyperbaric Surgery, University Medical School, Graz, Austria
  • 2 Department of Biomedical Engineering and Computing, University Medical School, Graz, Austria
Further Information

Publication History

Publication Date:
25 September 2003 (online)

Also available at
    Permissions and Reprints

Background and Study Aims: Experimental studies have shown that the cytotoxicity of porphyrins and related substances is mediated mainly by singlet oxygen and that hypoxic cells are less affected by porphyrins and light. In a clinical pilot study we assessed the use of photodynamic therapy (PDT) under hyperbaric oxygen (HBO), compared with PDT under normobaric conditions, in patients with advanced esophageal carcinoma.

Patients and Methods: After diagnostic work-up and staging, photosensitization in all patients was carried out using hematoporphyrine derivate (HpD) (2 mg/kg bodyweight 48 hours prior to PDT). We then applied light at 630 nm (KTP-Nd : YAG laser with DYE box) at dose of 300 J/cm, delivered by a fiber with a radial light-diffusing cylinder (length 1 cm), inserted through the biopsy channel of the endoscope. Of the patients, 14 (12 with stage III cancers, and two with stage IV cancers) were treated by PDT alone, and 17 patients (15 with stage III cancers, and two with stage IV cancers) received PDT under HBO at a level of 2 absolute atmospheric pressures (ATA). Transcutaneous PO2 levels of 500 - 750 mmHg under HBO, compared with transcutaneous PO2 levels of 60 - 75 mmHg under normobaric conditions, were measured.

Results: Improvements regarding dysphagia and stenosis diameter were obtained in both treatment arms with no significant differences (P = 0.36 and 0.14, respectively). The tumor length also decreased in both groups and showed a significant difference in favour of the PDT/HBO group (P = 0.002). Kaplan-Meier statistics showed median overall survival for the PDT group and the PDT/HBO group as 7.0 and 12 months respectively. The 12-month survival rate was 28.6 % for the PDT group and 41.2 % for the PDT/HBO group. Logrank test showed a difference in survival in favor of the PDT/HBO group (P = 0.059). No major treatment-related complication occurred, and the 30-day mortality rate was 0 %.

Conclusions: Combined PDT/HBO represents a new approach in the treatment of esophageal cancer which, in this pilot study, appears to have enhanced the efficiency of PDT.

References

  • 1 McCaughan J S Jr. Photodynamic therapy versus Nd : YAG laser treatment of endobronchial or esophageal malignancies. In: Spinelli P, Dal Fante M, Marchesini R (eds). Photodynamic therapy and biomedical lasers.  New York; Elsevier, 1992: 23-36
    Google Scholar
  • 2 Moan J, Peng Q, Sorensen R, et al. The biophysical foundations of photodynamic therapy.  Endoscopy. 1998;  30 387-391
    PubMedGoogle Scholar
  • 3 See K, Forbes I, Betts W. Oxygen dependency of phototoxicity with haematoporphyrin derivative.  Photochem Photobiol. 1986;  44 711-716
    PubMedGoogle Scholar
  • 4 Gomer C, Razum N. Acute skin response in albino mice following porphyrin photosensitization under oxic and anoxic conditions.  Photochem Photobiol. 1984;  40 435-439
    PubMedGoogle Scholar
  • 5 Gibson S L, Hilf R C. Interdependence of fluence, drug dose and oxygen on haematoporphyrin derivative induced photosensitization of tumour mitochondria.  Photochem Photobiol. 1985;  42 367-373
    PubMedGoogle Scholar
  • 6 Jirsa M, Pouckiva P, Dolezal J, et al. Hyperbaric oxygen and photodynamic therapy in tumor-bearing nude mice.  Eur J Cancer. 1991;  27 (1) 109
    PubMedGoogle Scholar
  • 7 Dong G C, Hu S X, Zhao G Y, et al. Experimental study on cytotoxic effects of hyperbaric oxygen and photodynamic therapy on mouse transplanted tumor.  Clin Med J (Engl). 1987;  100 697-702
    PubMedGoogle Scholar
  • 8 McCaughan J S, Ellison E C, Guy J T, et al. Photodynamic therapy for esophageal malignancy: a prospective twelve-year study.  Ann Thor Surg. 1996;  62 1005-1010
    PubMedGoogle Scholar
  • 9 Heier S K, Rothman K A, Heier L M, Rosenthal W S. Photodynamic therapy for obstructing esophageal cancer: light dosimetry and randomized comparison with Nd : YAG laser therapy.  Gastroenterology. 1995;  109 63-72
    PubMedGoogle Scholar
  • 10 Van den Bergh H. On the evolution of some endoscopic light delivery systems for photodynamic therapy.  Endoscopy. 1998;  30 392-407
    PubMedGoogle Scholar
  • 11 Gray B J, Heaton R W, Henderson A, Hutchinson D CS. In vivo calibration of a transcutaneous oxygen electrode in adult patients. In: Huch A, Huch R, Rooth G (eds). Continuous transcutaneous monitoring: Advances in experimental medicine and biology.  New York; Plenum Press, 1987: 75-78
    Google Scholar
  • 12 Overhold B F, Panjehpour M. Photodynamic therapy for Barrett's esophagus: clinical update.  Am J Gastroenterol. 1996;  91 (9) 1719-1723
    PubMedGoogle Scholar
  • 13 Sibille A, Lambert R, Souquet J C, et al. Long-term survival after photodynamic therapy for esophageal cancer.  Gastroenterology. 1995;  108 337-344
    PubMedGoogle Scholar
  • 14 Liang-Shun-Wang L S, Kwan-Hwa-Chi K H, Maw-Hwa-Hu M L, et al. Management for patients with advanced T4 epermoid carcinoma of the esophagus.  J Surg Oncol. 1996;  62 (1) 22-29
    CrossrefPubMedGoogle Scholar
  • 15 Segalin A, Little A G, Ruol A, et al. Surgical and endoscopic palliation of esophageal carcinoma.  Ann Thor Surg. 1989;  48 (2) 267-271
    PubMedGoogle Scholar
  • 16 Ell C. Clinical photodynamic therapy: where is it heading?.  Endoscopy. 1998;  30 408-411
    PubMedGoogle Scholar
  • 17 Lightdale C J, Heier S K, Marcon N E, et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd : YAG laser for palliation of esophageal cancer: a multicenter randomized trial.  Gastrointest Endosc. 1995;  42 507-512
    CrossrefPubMedGoogle Scholar
  • 18 Scheider D M, Siemens M, Cirocco M, et al. Photodynamic therapy for the treatment of tumor ingrowth in expandable esophageal stents.  Endoscopy. 1997;  29 (4) 271-274
    PubMedGoogle Scholar
  • 19 Foote C S. Mechanisms of photooxygenation. In: Doiron DR, Gomer CJ (eds). Porphyrin localization and treatment of tumors.  New York; Alan R. Liss, 1984: 3
    Google Scholar
  • 20 Diamond I, Granelli S G, McDonough A F, et al. Photodynamic therapy of malignant tumours.  Lancet. 1972;  2 117
    PubMedGoogle Scholar
  • 21 Wieman T J, Mang T S, Fingar V H. Effect of photodynamic therapy on blood flow in normal and tumor vessels.  Surgery. 1988;  104 512-517
    PubMedGoogle Scholar
  • 22 Clark J M. Oxygen toxicity. In: Bennett PB, Elliott DH (eds). The physiology and medicine of diving.  London; Baillière, Tindall and Cox, 1982 3rd edition: 200-238
    Google Scholar
  • 23 Lambertsen C J. Effects of hyperoxy on organs and their tissues. In: Rubin E (ed). Extrapulmonary manifestation of respiratory disease.  New York; Marcel Dekker, 1978: 239-303
    Google Scholar

M.D. A. Maier

Dept. Thorax- und Hyperbare Chirurgie Universitätsklinik für Chirurgie

Auenbruggerplatz 29

8036 Graz

Austria

Phone: +43-316-3852756

Email: alfred.maier@klinikum-graz.at

      >